Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo Save
Tofacitinib has been approved for use in rheumatoid arthritis. While attempts to prove its efficacy in psoriasis have not been successful (http://buff.ly/1R6aRF4), early uncontrolled reports have suggested its potential utility in other skin disorders.
Vitiligo is an autoimmune depigmenting disorder for which there is no effective therapy. Recent reports in JAMA dermatology have shown the efficacy of tofacitinib in patients with vitiligo (Citation source http://buff.ly/1Jo3dDe).
Alopecia universalis can be a devastatingly recalcitrant condition. Early uncontrolled reports of major improvement with ruxolitinib or tofacitinib has led to a randomized trial of tofacitinib in alopecial universalis (currently in progress). A recent report has also shown that tofacitinib may improve the nail dystrophy that accompanies this condition. (Citation source http://buff.ly/1kDXZHZ)
A similar report from researchers at Yale has shown the efficacy of uncontrolled tofacitinib in patients with severe eczema. (Citation source http://buff.ly/1Jo6Jh9)